NASDAQ: IDXX · Life Sciences · 6 alerts · CIK 874716
Share price
$700.65Close, Nov 16
Market cap
$55.2B
Shares outstanding
78.79MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Idexx Laboratories Inc filings on SEC EDGAR ↗
Idexx Laboratories Executive Chair of the Board Jonathan Jay Mazelsky Sells $17.7M of Stock
Jonathan Jay Mazelsky, Executive Chair of the Board, sold 25,140 shares of Idexx Laboratories Inc at $698.26 to $711.95 a share (average $703.19) in 13 transactions, worth $17.7M in total on Nov 4, 2026. Shares held after the trade: 83,803 (-0.4%).
Idexx Laboratories EVP Michael Lane Sells $2.74M of Stock
Michael Lane, EVP, sold 3,979 shares of Idexx Laboratories Inc at $687.46 to $689.70 a share (average $688.64) in 3 transactions, worth $2.74M in total on Nov 4, 2026. Shares held after the trade: 4,076 (-29.2%).
Idexx Laboratories EVP, GC & Corporate Secretary Sharon E. Underberg Sells $6.13M of Stock
Sharon E. Underberg, EVP, GC & Corporate Secretary, sold 8,906 shares of Idexx Laboratories Inc at $688.25 to $690.02 a share (average $688.59) in 3 transactions, worth $6.13M in total on Nov 4, 2026. Shares held after the trade: 7,169 (-12.8%).
Idexx Laboratories Insider Daniel M. Junius Sells $845K of Stock
Daniel M. Junius sold 1,200 shares of Idexx Laboratories Inc at $701.68 to $705.78 a share (average $704.07) in 2 transactions, worth $845K in total on Nov 4, 2026. Shares held after the trade: 2,361 (-17.5%).
IDEXX Laboratories reported total revenue of $1.21 billion for the quarter ended September 30, 2026, representing growth over the $1.11 billion reported in the prior year. Net income for the nine months ended September 30, 2026, increased to $934 million, up from $811 million in the same period of 2025, driven by strong performance in both product and service revenue.
IDEXX Laboratories reported third quarter 2026 revenue of $1.21 billion, up 10% year-over-year, driven by strong growth in its Companion Animal Group. The company delivered EPS of $4.01 and raised its full-year 2026 revenue and EPS guidance based on strong recurring diagnostics performance.
Term
Q3 2026
“IDEXX delivered exceptional third quarter results, reflecting strong commercial execution and momentum from our innovation-driven growth strategy. Innovations like IDEXX inVue Dx with FNA, and IDEXX Cancer Dx becoming a multi-cancer panel, are helping practices detect disease earlier and work more efficiently.”
Mike Erickson, President and Chief Executive Officer